These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
160 related items for PubMed ID: 19877884
1. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS. Cancer Biother Radiopharm; 2009 Oct; 24(5):543-50. PubMed ID: 19877884 [Abstract] [Full Text] [Related]
2. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. Róka R, Séra T, Pajor L, Thurzó L, Láng J, Csernay L, Pávics L. Orv Hetil; 2000 May 07; 141(19):1019-23. PubMed ID: 10846424 [Abstract] [Full Text] [Related]
3. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cheng A, Chen S, Zhang Y, Yin D, Dong M. Cancer Biother Radiopharm; 2011 Apr 07; 26(2):237-44. PubMed ID: 21539455 [Abstract] [Full Text] [Related]
4. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy. Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS. Q J Nucl Med Mol Imaging; 2011 Feb 07; 55(1):91-102. PubMed ID: 21068716 [Abstract] [Full Text] [Related]
5. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ. Nuklearmedizin; 2016 Sep 26; 55(5):188-95. PubMed ID: 27443809 [Abstract] [Full Text] [Related]
6. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Küçük NO, Ibiş E, Aras G, Baltaci S, Ozalp G, Bedük Y, Canakci N, Soylu A. Ann Nucl Med; 2000 Aug 26; 14(4):239-45. PubMed ID: 11023023 [Abstract] [Full Text] [Related]
7. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. Liepe K, Runge R, Kotzerke J. J Cancer Res Clin Oncol; 2005 Jan 26; 131(1):60-6. PubMed ID: 15449184 [Abstract] [Full Text] [Related]
8. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Liepe K, Kotzerke J. Nucl Med Commun; 2007 Aug 26; 28(8):623-30. PubMed ID: 17625384 [Abstract] [Full Text] [Related]
9. [Pain therapy with rhenium-186 HEDP in multiple bone metastases]. Palmedo H, Bender H, Schomburg A, Grünwald F, Schöneich G, Zamorra P, Reichmann K, Dierke-Dzierzon C, Mallmann P, Biersack HJ. Nuklearmedizin; 1996 Apr 26; 35(2):63-7. PubMed ID: 8721578 [Abstract] [Full Text] [Related]
10. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S, Biersack HJ. J Clin Oncol; 2003 Aug 01; 21(15):2869-75. PubMed ID: 12885803 [Abstract] [Full Text] [Related]
11. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases. Pirayesh E, Amoui M, Mirzaee HR, Tabei F, Rakhsha A, Kalantari BA, Shafiei B, Assadi M, Asli IN. J Nucl Med Technol; 2013 Sep 01; 41(3):192-6. PubMed ID: 23918612 [Abstract] [Full Text] [Related]
12. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Liepe K, Kropp J, Runge R, Kotzerke J. Br J Cancer; 2003 Aug 18; 89(4):625-9. PubMed ID: 12915868 [Abstract] [Full Text] [Related]
13. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer. Leondi AH, Souvatzoglou MA, Rapti AS, Leontopoulou SA, Papadaki EK, Datseris EI, Anagnostopoulou US, Zerva CJ. Q J Nucl Med Mol Imaging; 2004 Sep 18; 48(3):211-9. PubMed ID: 15499295 [Abstract] [Full Text] [Related]
14. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S. Q J Nucl Med Mol Imaging; 2006 Dec 18; 50(4):355-62. PubMed ID: 17043634 [Abstract] [Full Text] [Related]
15. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG. J Nucl Med; 2003 Jun 18; 44(6):953-60. PubMed ID: 12791825 [Abstract] [Full Text] [Related]
16. [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. Liang JG, Jiang NY, DU JQ, Lu XP, Liu XG, Chen SX. Zhonghua Zhong Liu Za Zhi; 2005 Mar 18; 27(3):180-2. PubMed ID: 15946573 [Abstract] [Full Text] [Related]
17. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. Israel O, Keidar Z, Rubinov R, Iosilevski G, Frenkel A, Kuten A, Betman L, Kolodny GM, Yarnitsky D, Front D. J Clin Oncol; 2000 Jul 18; 18(14):2747-54. PubMed ID: 10894875 [Abstract] [Full Text] [Related]
19. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdes Olmos RA. Urol Int; 2006 Jul 18; 77(1):50-6. PubMed ID: 16825816 [Abstract] [Full Text] [Related]